Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 3Completed 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 35Multiple Myeloma 31Lymphoma, Non-Hodgkin 29Burkitt Lymphoma 29Lymphoma 27Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Recurrence 23Hematologic Neoplasms 22Lymphoma, B-Cell 21Lymphoma, Follicular 20Melanoma 16Ovarian Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Neoplasm Metastasis 14Leukemia 14Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Lymphoma, T-Cell, Peripheral 9

Interventions

dinutuximab 3Cyclophosphamide 3Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2Doxorubicin 2Cisplatin 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1lorlatinib 1fludarabine 1etoposide phosphate 1Transurethral Resection of Bladder 1Razoxane 1Radiotherapy 1Proton Therapy 1Nuclear Medicine Department, Hospital 1Leukapheresis 1Influenza Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Ganglioneuroblastoma × Cyclophosphamide × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
CNS

Neuroblastoma, Recurrence, Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡